Dr John Brown has been appointed first chair of the Cell Therapy Catapult centre, a new initiative from the UK’s Technology Strategy Board that focuses on the cell therapy industry.
He will lead the centre as it provides with access to finance, clinical and technical expertise to biotech companies involved in cell therapy technology in an aim to make the UK a global leader in the sector.
This includes helping to turn innovations in cell therapies into commercial products for use as medicines.
“This is an exciting time for the Cell Therapy Catapult, as it is only weeks away from opening its doors,” said minister for universities and science David Willetts.
“John Brown has a wealth of experience in running businesses in the life sciences sector, and the skills he can bring to the table are exactly what we need to help get this latest Catapult off the ground.”
Dr Brown has great experience in the life sciences industry, holding such positions as chairman of medical diagnostics company Axis-Shield and chair of specialist healthcare company, BTG.
He has also spent time as CEO and finance director of UK vaccine company Acambis.
Dr Brown said: “The Cell Therapy Catapult will position the UK as the leader in this new area of medicine. Translating great science into products will deliver benefits both for patients but also our economy and I’m delighted to have the opportunity to build on the great foundation of work that the Technology Strategy Board has already done.”
His appointment was welcomed by the BioIndustry Association (BIA), of which Dr Brown is a board member.
“John’s presence on our board and as chair of the Catapult will make sure that strong links are developed and maintained between the two organisations,” said Steve Bates, CEO of the BIA.